DMAC DiaMedica Therapeutics Inc

Price (delayed)

$5.81

Market cap

$313.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.71

Enterprise value

$308.41M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 4

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases.

Highlights
DMAC's debt is down by 33% year-on-year and by 12% since the previous quarter
DiaMedica Therapeutics's equity has increased by 39% YoY but it has decreased by 16% from the previous quarter
The quick ratio has contracted by 23% from the previous quarter but it has grown by 14% YoY
The net income has contracted by 30% YoY and by 7% from the previous quarter
The company's EPS fell by 11% YoY

Key stats

What are the main financial stats of DMAC

DMAC stock price

How has the DiaMedica Therapeutics stock price performed over time
Intraday
2.83%
1 week
-5.68%
1 month
-3.97%
1 year
38.33%
YTD
-27.01%
QTD
-14.18%

Financial performance

How have DiaMedica Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$36.73M
Net income
-$35.16M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 30% YoY and by 7% from the previous quarter
The operating income has contracted by 26% YoY and by 7% from the previous quarter

Price vs fundamentals

How does DMAC's price correlate with its fundamentals

Growth

What is DiaMedica Therapeutics's growth rate over time

Valuation

What is DiaMedica Therapeutics stock price valuation
P/E
N/A
P/B
6.63
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 11% YoY
The stock's price to book (P/B) is 90% more than its 5-year quarterly average of 3.4 but 8% less than its last 4 quarters average of 7.0
DiaMedica Therapeutics's equity has increased by 39% YoY but it has decreased by 16% from the previous quarter

Efficiency

How efficient is DiaMedica Therapeutics business performance
DiaMedica Therapeutics's return on invested capital has decreased by 30% YoY
DiaMedica Therapeutics's return on equity has decreased by 26% YoY
The return on assets has declined by 25% year-on-year

Dividends

What is DMAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DMAC.

Financial health

How did DiaMedica Therapeutics financials performed over time
The total assets is up by 37% year-on-year but it is down by 14% since the previous quarter
The quick ratio has contracted by 23% from the previous quarter but it has grown by 14% YoY
DMAC's debt is 100% smaller than its equity
DiaMedica Therapeutics's debt to equity has plunged by 100% YoY
DiaMedica Therapeutics's equity has increased by 39% YoY but it has decreased by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.